Navigation Links
Help for Psoriasis

New research shows the drug efalizumab may reduce symptoms of psoriasis and improve patients’ quality of life.//

Researchers from Loyola University studied more than 550 patients who had psoriasis. Patients received weekly injections of efalizumab (Raptiva) or a placebo for three months. Researchers evaluated the extent of each patient’s condition and rated the degree of scaling and thickness. Patients also completed a questionnaire that measured their quality of life and severity of symptoms.

Results of the study show patients who received efalizumab experienced a significant improvement in their symptoms and quality of life. Patients were considered to have improved if they scored at least 75 percent on the Psoriasis Area and Severity Index. Twenty-seven percent of the patients treated with efalizumab scored at least 75 percent, while only 4 percent of patients in placebo group achieved this score. Patients who took efalizumab also reported a better quality of life than those in the placebo group.

Efalizumab is a biologic drug that blocks immune cells. Researchers say the drug modulates T-cells, which bolster the body’s immune response. Kenneth Gordon, M.D., from the Loyola Psoriasis Center, says, “Biologics are injected, instead of swallowed and block immune cells that produce the dry, flaky skin.”

Psoriasis is triggered by an immune system response that causes skin cells to grow too quickly. The skin cells do not mature normally, and the skin piles up, causing red, scaly lesions to form. About 5 million people in the United States are affected by psoriasis. There is currently no cure, but researchers say new treatments, including biologics, are helping to improve the condition for many patients.

'"/>




Page: 1

Related medicine news :

1. New and unique treatment for Psoriasis patients
2. Comparing Psoriasis Treatments
3. Psoriasis Increases Cancer Risk
4. Managing Patients With Psoriasis
5. Effective Treatment Option For Psoriasis
6. Smoking Aggravates Psoriasis
7. Remicade Emerges as a Treatment for Patients Suffering From Psoriasis Disorder
8. Short-Term Topical Corticosteroid May Offer Relief for Certain Type of Psoriasis
9. Psoriasis raises risk for heart attack
10. Psoriasis Associated With Increased Risk For Heart Attack
11. Remicade Therapy Effective in Treating Severe Psoriasis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film Studios Announced ... "This new layered style transition tool will keep a consistent flow to your project ... Film Studios. , TranSweep is an all new layered style transition tool for ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dalton Pharma Services, ... has successfully completed another Health Canada inspection and has received a compliant rating ... resulted from a Good Manufacturing Practices (GMP) inspection conducted at Dalton’s facility during ...
(Date:5/26/2016)... ... 26, 2016 , ... Women’s athletic apparel company GRACEDBYGRIT is ... shop for three consecutive weekends. The pop-up shop is a great way to ... community full of women who appreciate the most premium goods and vibrant events. ...
(Date:5/26/2016)... ... 26, 2016 , ... Bunion Bootie is a great option for ... save. For a limited time only (offer expires May 31, 2016) customers can save ... by using the promo code "Memorial" at checkout. The more Bunion Booties purchased, the ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... Association/American Stroke Association's Get With The Guidelines®-Stroke Gold Plus Achievement Award with ... second for Memorial Healthcare System, recognizes its commitment to emergency stroke care ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 2016 Since its commercial introduction ... essential life science tool for conducting genetic studies in ... reveals in its new report that the industry sits ... powered by a range of new applications in the ... http://photos.prnewswire.com/prnh/20140723/694805 ) , Since the ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... Frankfurt Prime Standard: QIA) today announced that the company has ... GmbH to develop and commercialize predictive assays in oncology. An ... a marker to predict effectiveness of anthracycline treatment in triple ... are pleased to partner with Therawis, which developed the PITX2 ...
(Date:5/25/2016)... As illustrated by the Spring ... the numbers and momentum of cannabis in the US ... billions, more research and development push the sector forward. ... Legal Marijuana Markets Report  from from ArcView Market Research ... the increase in sector is attributed to adult use ...
Breaking Medicine Technology: